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Several investigators have reported the use of trensesophageal echocardiography during interventional catheterzation procedures (1) (2) (3) (4) (5) (6) (7) . Trasesophsged echocardiography does not interfere with execution of the procedure and generally provides superior image quality . In this report, we describe the use of trasesophageal echocardiographic guidance of transcatheter device occlusion of ventricular septa) defects. Possible indications for the use of tansesophageal echocardiography during the procedure, the contributions of trasesophageal echocardiography to correct device positioning and assessment of results are discussed .
Methods
The medical records, angiograms and echocardiograms of all patients who underwent trans:atheter ventricular septal defect closure between February I, 1990 and November 1, 1992 and who had a transesophageal echocardiogram during the procedure were reviewed. Patients were identified by a search of the computerized data bases for echocardiography and closure devices. Before February, 1990, trasesophage-al echocardiography was not used during transcatheter Ventricular septa) defect closure .
Informed consent. The Bard Clamshell Septa) Occluder used for ventricular septa) defect closure is investigational, and its use is currently restricted to centers designated by the Food and Drug Administration . The device placement protocol has been approved by the Food and Drug Administration and by the Committee on Clinical Investigation at Children's Hospital . Informed consent was obtained before a( device placements.
Echocardiographic examination . All patients who were candidates fur tt-anscatheter ventricular septal defect closure underwent conventional surface echocardiographic examination before catheterization . Transesophageal echocardiography was used during ventricular septal defect closure in patients who were in one or more of several higher risk Categories : I) multiple ventricular septal defects requiring device closure ; 2) anticipation of multiple additional interventional procedures and angiograms during the same catheterization (high contrast load) ; 3) complex septal anatomy (such as malalignment of the apical septum) : and 4) ventricular septal defect in close proximity to valve structures .
Transesophageal echocardiography was performed by one of four faculty echocardiographers, using a Hewlett-Packard Sonos 1000 or 1500 or an Acuson 128 phased-ay imaging system equipped with pulsed, continuous wav y nd color Doppler and a single-plane or biplane transesophageal echocardiographic transducer. A pediatric transducer was used in patients weighing < 10 to 12 kg . All patients underwent general anesthesia and intubation before transesophageal echocardiography, to prevent patient movement during ventricular septa) defect device deployment .
Methodology for transesophageal echocardiugraphic guidance of transcatheter ventricular septal defect closure has been described elsewhere (1) . Ventricular septal defect anatomy, size, relation of multiple defects, if present . and proximity to valves and other cardiac structures were determined before device placement . Occluder arm position was monitored during device delivery and after release, and effectiveness of closure was evaluated using Doppler color flow mapping.
Cardiac catheterization and ventricular septal defect closure. Baseline hemodynamic variables were measured before ventricular septal defect closure . Candidacy for transcatheter closure and the details of the procedure have been described elsewhere (8, 9) . Devices used for ventricular septal defect occlusion included the Bard Clamshell Septal Umbrella (17, 23, 28, 33 or 40 mm in diameter) and the Bard PDA Umbrella (12 or 17 mm in diameter) . Device position was assessed by fluoroscopy throughout the procedure and afterward by angiography, when possible. The techniques forother interventional procedures performed in some of the patients have been described elsewhere (10) (11) (12) . 1661 
Results
Patient characteristics. Between February 1990 and November 1992, a total of 83 catheterizations involving transcatheter ventricular septal defect closure were performed . Thirty-one of these catheterizations (37%) were done using transesophageal echocaroiographic guidance ; the clinical characteristics of 29 patients undergoing these 31 catheterizations are described in Table I (median age 7 .2 years, range 12 months to 80 years ; median weight 19.5 kg, range 6.3 to 75) .
Ventricular septa) defect was the primary cardiac diagnosis in 7 of 29 patients. The other 22 patients included 9 with double-outlet right ventricle or transposition of the great arteries with ventricular septa) defect status post Rastelli repair (8) or arterial switch and ventricular septa) defect closure (1)f 5 with repaired tetralogy of Fallot or tetralogy of Fallot with pulmonary atresia ; 5 with an unrepuired conotruncal malformation with multiple ventricular septa) defects : I with double-outlet right ventricle with inverted atria status post Senning and Rastelli ; and 2 with a postinferction ventricular septa) defect .
These 29 patients underwent placement of 45 ventricular septa) defect devices (43 clamshells, 2 patent ductus arteriosus umbrellas) in 23 muscular ventricular septal defects, 17 patch mai :in defects, 2 left ventricular to right atria] shunts, 2 postinfarction defects and'] fenestration in a ventricular septa) defect patch-More than one inlerventional procedure was performed during 19 (62%) of the 31 cardiac catheterizations ! Table 2 ) . Additional procedures included device closure of an atria' septal defect or of one or more additional ventricular Sept, defects, balloon dilation of pulmonary arteries or of the right or left ventricular outflow met, stent placement and coil embolization of aortopulmonary collateral vessels .
Fluoroscopic and angiographic evaluation. Device position . After device release, the relation between the device arms and the ventricular septum could be accurately determined by fluoroscopy and angiography in 35 of 45 devices, Of these . 32 devices appeared to be correctly positioned, whereas in the other 3 one or two arms appeared to be on the wrong side of the septum . The relation of the device arms to the septum could not be determined with certainty in the remaining !0 devices .
Relation to valves. Device arms were thought to be within 5 mm of aortic leaflets in seven devices and tricuspid valve apparatus in five. The relation of device arms to valve structures could not be determined by fluoroscopy and angiography in four patients .
Residual flow . Angiography, performed after release of 37 devices, was helpful in assessing ventricular septal defect closure in only 11 (30%), with residual flow graded as trivial in 4 . small in 3 and moderate in 4 . Angiography was not performed after placement of seven devices because of contrast load limitations and after another because of device embolization . In summary, fluoroscopy and angiography were inadequate for assessment of device position in 22% and for proximity to valve tissue in W/o of the ventricular septa) defect devices placed . The amount of residual flow could not be assessed in 70% of the devices evaluated by angiography .
Transesophageal echocardiographic evaluation . Device position. The relation of device arms to the ventricular septum was demonstrated by transesophageal echocardiography in 40 of the 45 devices, although in 2 cases one or two arms were not well imaged. Because of extreme anterior location or acoustic shadowing by patch material, five devices were difficult to image .
Relation to valves . Of the 45 devices, 12 were considered close to valve tissue (6 aortic, 6 tricuspid), including 2 cases where the device relation to valve structures could not be assessed by fluoroscopy or angiography . The remaining devices, including those indistinctly imaged, were thought to be distant from the valves . ]'we devices were considered by angiography to be close to valve structures but were seen as remote by transesophageal echocardiography ; review of angiograms and echocardiograms in these two cases revealed that in one the distance to the aortic valve was difficult to determine with certainty by transesophageal echocardiography (and was close by angiography) ; in the other, review of the angiogram concurred with transesophageal echocardiography that the device was not within 5 mm of the aortic valve.
Residual flow, Residual shunting through the ventricular septal defect as assessed by color flow mapping after device placement was absent in five cases, trivial in six, small in eight, moderate in two and large in three . In I I other defects the amount of flow was significantly reduced but could not Table 1 . be graded accurately. The amount of residual flu, after device placement could not be determined by transesophugeal echocardiography in the remaining nine cases.
In summary, Iransesophageal echocardiography was inadequate for assessment of device arm position in 11% and for residual flow in 20% of devices placed. Proximity to valve tissue could be assessed in 98% of devices .
-Additional information obtained by transesophageal echocardiography . Previously unrecognized cardiac abnormalities were discovered in several patients . Large residual interatrial communications were found in two patients who had undergone reparative surgery (one with juxtaposition of the atria) appendages. one with a Senning procedure far inverted atria). These defects had not been detected by routine hemodynamic evaluation before transesophageai echocardiography . In five other postoperative patients (all >5 years old), a patent foramen ovate or small atria) septal defect with detectable flow was identified . Malalignment of the muscular septum apical to the ventricular septal defect was diagnosed in three patients . Two large atria] thrombi were detected in a patient with a postinfarction ventricular septal defect.
Resource utilization. The average duration of transesophageal echocardiographic imaging during transcaiheter ventricular septal defect closure in these 31 catheterizations was 2 .15 h (range 0 .55 to 5 .23). No morbidity related to transesophageal echocardiography was observed .
Combined assessment by catheterization and transesophagealechocardlography. Of the five devices poorly imaged by transesophageal echocardiography, three were well imaged VAN 
Discussion
Use of transesophageal echocardiography to guide several types of in!erventional procedures has been previously described, including mitral valvuloplasty (2,3), atrial septal defect device placement (4), balloon atrial septostomy (5), endomyocardinl biopsy in infants (6) and radiofrequency ablation of bypass tracts (7) . We have previously described our early experience with transesophageal echocardiographic guidance of transcatheterclosure of several intracardiac defects (I) .
Device position. During transcatheter closure of ventricular septal defects, deployment of device arms is guided radiographically using landmarks, such as sternal wires and ribs, because septal and valve structures cannot be visualized fluoroseopically unless extensively calcified (Fig . 2) . After delivery of the distal set of arms, tension on the device causes the arms to move in predictable directions if they are properly positioned. However, device arms caught on other cardiac structures (such as valve tissue) may mimic properly positioned arms. In addition, manipulation of the device to assess position can cause arm dislodgment . Interference with valve structures may not be apparent until the device is released, and angiography performed . Transesophageal echocardiography during device deployment allows continuous visualization of device arms and their proximity to the septum and other cardiac structures in the great majority of patients ( Fig . I and 3 ). Arms that are positioned improperly or that interfere with valve function can be identified before the proximal portion of the device is deployed, while retraction and redelivery are still possible . Incorrect arm position appears less likely if tmnsesophageal echocardiographic guidance is used, Although some defects (particularly very anterior ones) can be difficult to image with tmnsesophageal echocardiography, the combination of trausesophageal echocardiography and fluoroscopy is likely to provide the most accurate assessment of device position.
Residual Bow. The angiographic assessment of residual flow is affected by the amount of contrast medium used, proximity of the injection to the defect and the time elapsed since device placement . Transesophageal echocardiography may provide a more physiologic assessment of residual flow and can be performed at multiple intervals after device placement.
In 20 ventricular septa) defect devices with inconclusive angiograms, transesophageat echocardiography provided enough information about the amount and location of residual flow that further angiography was not necessary. Use of trnsesophageal echocardiography in such situations reduces contrast load and radiation, increasing the number of diagnostic and interventional procedures that can be performed during a single catheterization. Further catheterizations, in turn, may be avoided .
At our institution, transcatheter device closure is used increasingly for management of selected unoperated ventricular septa) defects (9) . Transcatheter closure of residual postoperative defects has also proved useful as an alternative to reoperation, particularly for poor operative candidates (13) . Although experience with transcatheter closure of postinfarction ventricular septa) defects is limited (8, 14) , further experience may identify patients in whom transcatheter closure improves survival . Fgure C Angiogram after placement of the device shown in Figure  3 . The location of the residual flow across the septum (i .e., through the same defect or a separate defect at the same level) is difficult to determine by algography alone . Figure 4 , demonstrating that the flow is not around the device shown in Figures 3 and 4 but is instead through a separate defect that is more posterior in the midmuscular septum . vsd = ventricular septa) defect ; other abbreviations as in Figure 3 .
Indications for tranaosopbageal echocardiography. On review of the 83 catheterizations involving ventricular septal defect device placement performed during the study period, transesophageal echocardiographic guidance appears to be indicated when I) the ventricular septal defect is near semilunar or atrioventticular valve tissue ; 2) the defect is very large or complex, or septal anatomy is unusual (as with malalignment of the apical portion of the septum) ; 3) the location or number of ventricular septal defects is still in question after conventional echocardiographv and angiogmphy; or 4) the need for multiple interventional procedures during the same catheterization is anticipated ( Fig. 4 and 5 ).
Other indications for ttansesophageal echocardiogmphic guidance of the procedure might include renal failure or allergy to contrast material .
Advastages of Iraaaesophageal echocardiography over conventload echocardiography . The superior imaging capability oftransesophageal echocardiography compared with surface echo has been well described . Transesophageal echocardiography may identify previously unrecognized but important cardiac abnormalities, as our study population revealed . More important for transcatheter closure of cardiac defects, however, is the ability to continuously monitor device position and relation to valve tissue during device delivery without interrupting or interfering with fluoroscopy or catheter manipulation (1, 2) .
Study limhatbns. Very anterior ventricular septa] defects and some apical defects can be difficult to image by transesophageal echocardiography . Technologic advances may improve far-field penetration and resolution . Conventional echocardiography, although it may provide superior VAN DER VELDE ET AL . 1665 TRANSESOPHAGBAL ECHO FOR CATHETER VSD CLOSURE images of these areas, is likely to interfere with the closure procedure and has not been useful . General anesthesia is necessary to prevent patient movement during transcatheter ventricular septal defect closure, particularly if transesephageal echocardiography is used.
Resource utilization . Transesophageat echocardiographic guidance of transcother ventricular septal defect closure requires a time commitment by the echocandiographer and equipment that may be prohibitive in some situations .
Conclusions . Transesophageal echocardiography is a useful and frequently necessary adjunct to fluoroscopy and angiography for guidance of transcatheter ventricular septa] defect closure and is especially indicated when positioning of the device is likely to be difficult or to interfere with valve structures or when multiple interventional procedures are anticipated .
